AARTIPHARM · Aarti Pharmalabs Limited · Financials
Volume · Nov 13
35.75K
Avg daily vol (3M)
41.47K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
18.19B
-14%
FY2026
Net Income
1.73B
-36.6%
FY2026
Operating Cash Flow
2.62B
-21%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| INR | 21.61B | 18.19B | 21.15B | 18.53B | 19.45B |
| INR | 1.17B | 1.04B | 869.04M | 732.35M | 625.4M |
| INR | 572.67M | 469.03M | 268.96M | 172.14M | 210.5M |
| INR | — | — | 3.61B | 3B | 2.61B |
| INR | 839.03M | 582.14M | 882.85M | 835.9M | 672.8M |
| INR | 2.53B | 1.73B | 2.72B | 2.16B | 1.93B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2026: 861.03M in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.